Suppr超能文献

[107例输入性成人疟疾病例的回顾性分析。成人单纯性恶性疟口服阿托伐醌-氯胍治疗的经验报告]

[Retrospective analysis of 107 imported adult cases of malaria. Experience report of uncomplicated falciparum malaria treatment in adults with oral atovaquone-proguanil].

作者信息

Vatan Rémy, Pistone Thierry, Millet Pascal, Etienne Gabriel, Mercié Patrick, Longy-Boursier Maïté, Malvy Denis

机构信息

Service de Médecine Interne et des Maladies Tropicales, Hôpital Saint-André, Bordeaux.

出版信息

Presse Med. 2006 Apr;35(4 Pt 1):571-7. doi: 10.1016/s0755-4982(06)74642-5.

Abstract

OBJECTIVES

The principal aim of this study was to assess the efficacy of the combination of oral atovaquone and proguanil (AP) in routine treatment of uncomplicated falciparum malaria in recent visitors to the tropics. We also analyzed the epidemiologic, clinical and hematologic characteristics of these patients with imported malaria.

METHODS

This retrospective study reviewed the records of 107 cases of imported malaria, treated in the Tropical Disease Unit of Bordeaux University Hospital (France).

RESULTS

More than 75% had uncomplicated falciparum malaria; 10 developed complications, and one died. Average time from fever onset to first medical consultation was 4.8 days. Less than 10% had used physical measures of prevention against mosquito bites, and nearly 65% had not used chemoprophylaxis. The most frequent hematologic abnormalities were eosinopenia (84%) and thrombocytopenia (75%). In more than 30% of cases, another disease was also present. The oral AP combination was administered to more than 86% of patients with uncomplicated falciparum malaria (n=72). Tolerance was excellent and only one treatment failure was observed, associated with digestive disorders.

CONCLUSION

Better information for travelers and general practitioners is required to reduce the number of cases of imported malaria and to shorten the delay between symptom onset and specific treatment. The oral AP combination appears to be a safe and effective treatment for uncomplicated imported falciparum malaria.

摘要

目的

本研究的主要目的是评估口服阿托伐醌和氯胍(AP)联合用药在热带地区近期旅行者单纯性恶性疟原虫疟疾常规治疗中的疗效。我们还分析了这些输入性疟疾患者的流行病学、临床和血液学特征。

方法

这项回顾性研究回顾了法国波尔多大学医院热带病科治疗的107例输入性疟疾患者的记录。

结果

超过75%的患者患有单纯性恶性疟原虫疟疾;10例出现并发症,1例死亡。从发热开始到首次就医的平均时间为4.8天。不到10%的人采取了物理防蚊措施,近65%的人未使用化学预防药物。最常见的血液学异常是嗜酸性粒细胞减少(84%)和血小板减少(75%)。超过30%的病例还患有其他疾病。超过86%的单纯性恶性疟原虫疟疾患者(n = 72)接受了口服AP联合用药治疗。耐受性良好,仅观察到1例治疗失败,与消化系统疾病有关。

结论

需要为旅行者和全科医生提供更好的信息,以减少输入性疟疾病例数量,并缩短症状出现与特异性治疗之间的延迟。口服AP联合用药似乎是治疗单纯性输入性恶性疟原虫疟疾的一种安全有效的方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验